Interestingly, this dual checkpoint-targeted therapy was not associated with an increase in TRAEs or irAEs compared with what is expected for checkpoint-targeted monotherapy, unlike what is observed with combination checkpoint blockade therapies with PD-1 and CTLA-4 inhibition in NSCLC and melanoma.24 A pooled incidence of irAEs from combination immune checkpoint therapy25 compared with this trial showed an incidence of 32.7% vs 6.8% for all-grade diarrhea, 31.4% vs 5.3% for pruritus, and 27.1% vs 11.3% for rash, respectively. Here, CTLA4 is linked to Pruritus.